The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells

Lundsten,Sara; Spiegelberg,Diana; Stenerlöw,Bo; Nestor,Marika

doi:10.3892/ijo.2019.4888

The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells

Authors:
- Sara Lundsten
- Diana Spiegelberg
- Bo Stenerlöw
- Marika Nestor
View Affiliations

Affiliations: Department of Immunology, Genetics and Pathology, Uppsala University, 751 87 Uppsala, Sweden
Published online on: September 30, 2019 https://doi.org/10.3892/ijo.2019.4888
Pages: 1287-1295
Copyright: © Lundsten et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

177Lu‑DOTATATE was recently approved for the treatment of somatostatin receptor (SSTR)‑positive neuroendocrine tumors (NETs). However, despite impressive response rates, complete responses are rare. Heat shock protein 90 (HSP90) inhibitors have been suggested as suitable therapeutic agents for NETs, as well as a potential radiosensitizers. Consequently, the aim of this study was to investigate whether the HSP90‑inhibitor onalespib could reduce NET cell growth and act as a radiosensitizer when used in combination with 177Lu‑DOTATATE. The NET cell lines BON, NCI‑H727 and NCI‑H460, were first characterized with regards to 177Lu‑DOTATATE uptake and sensitivity to onalespib treatment in monolayer cell assays. The growth inhibitory effects of the monotherapies and combination treatments were then examined in three‑dimensional multicellular tumor spheroids. Lastly, the molecular effects of the treatments were assessed. 177Lu‑DOTATATE uptake was observed in the BON and NCI‑H727 cells, while the NCI‑H460 cells exhibited no detectable uptake. Accordingly, 177Lu‑DOTATATE reduced the growth of BON and NCI‑H727 spheroids, while no effect was observed in the NCI‑H460 spheroids. Onalespib reduced cell viability and spheroid growth in all three cell lines. Furthermore, the combination of onalespib and 177Lu‑DOTATATE exerted synergistic therapeutic effects on the BON and NCI‑H727 spheroids. Western blot analysis of BON spheroids revealed the downregulation of epidermal growth factor receptor (EGFR) and the upregulation of γ H2A histone family member X (γH2AX) following combined treatment with onalespib and 177Lu‑DOTATATE. Moreover, flow cytometric analyses revealed a two‑fold increase in caspase 3/7 activity in the combination group. In conclusion, the findings of this study demonstrate that onalespib exerts antitumorigenic effects on NET cells and may thus be a feasible treatment option for NETs. Furthermore, onalespib was able to synergistically potentiate 177Lu‑DOTATATE treatment in a SSTR‑specific manner. The radiosensitizing mechanisms of onalespib involved the downregulation of EGFR expression and the induction of apoptosis. Consequently, the combination of onalespib and 177Lu‑DOTATATE may prove to be a promising strategy with which to improve therapeutic responses in patients with NETs. Further studies investigating this strategy in vivo regarding the therapeutic effects and potential toxicities are warranted to expand these promising findings.

View Figures

View References

1	Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, Oei HY, de Jong M, Visser TJ, Reijs AE, et al: Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 733:496–506. 1994. View Article : Google Scholar : PubMed/NCBI
2	Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, et al: Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 376:125–135. 2017. View Article : Google Scholar : PubMed/NCBI
3	Kratochwil C, Lopez-Benitez R, Mier W, Haufe S, Isermann B, Kauczor HU, Choyke PL, Haberkorn U and Giesel FL: Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 18:595–602. 2011. View Article : Google Scholar : PubMed/NCBI
4	Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, Li SR, Angelberger P, Raderer M, Wogritsch S, et al: Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreo-tide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 12(Suppl 2): S41–S45. 2001. View Article : Google Scholar
5	Claringbold PG, Price RA and Turner JH: Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 27:561–569. 2012. View Article : Google Scholar : PubMed/NCBI
6	Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U and Morgenstern A: ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience. Eur J Nucl Med Mol Imaging. 41:2106–2119. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chan HS, Konijnenberg MW, Daniels T, Nysus M, Makvandi M, de Blois E, Breeman WA, Atcher RW, de Jong M and Norenberg JP: Improved safety and efficacy of ²¹³Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendo-crine tumors in mice pre-treated with L-lysine. EJNMMI Res. 6:832016. View Article : Google Scholar
8	Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R and Essler M: Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuro-endocrine tumors. Clin Cancer Res. 14:3555–3561. 2008. View Article : Google Scholar : PubMed/NCBI
9	Maier P, Hartmann L, Wenz F and Herskind C: Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int J Mol Sci. 17:pii: E102. 2016. View Article : Google Scholar : PubMed/NCBI
10	Den RB and Lu B: Heat shock protein 90 inhibition: Rationale and clinical potential. Ther Adv Med Oncol. 4:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
11	Pennisi R, Ascenzi P and di Masi A: Correction: Pennisi, R., et al. Hsp90: A new player in DNA repair? Biomolecules. 2015.5:2589–2618, Biomolecules 6: pii: E40, 2016. View Article : Google Scholar : PubMed/NCBI
12	Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH and Ames MM: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas. 42:411–421. 2013. View Article : Google Scholar :
13	Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM and Ames MM: Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer. 17:623–636. 2010. View Article : Google Scholar : PubMed/NCBI
14	Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H and Höpfner M: Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol. 40:1659–1667. 2012.PubMed/NCBI
15	Zitzmann K, Ailer G, Vlotides G, Spoettl G, Maurer J, Göke B, Beuschlein F and Auernhammer CJ: Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. Int J Oncol. 43:1824–1832. 2013. View Article : Google Scholar : PubMed/NCBI
16	Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
17	Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI
18	Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, et al: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet. 387:968–977. 2016. View Article : Google Scholar
19	Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A and Wolin EM: Everolimus plus octreo-tide long-acting repeatable in patients with advanced lung neuroendocrine tumors: Analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 143:955–962. 2013. View Article : Google Scholar
20	Hong DS, Banerji U, Tavana B, George GC, Aaron J and Kurzrock R: Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treat Rev. 39:375–387. 2013. View Article : Google Scholar
21	Shapiro GI, Kwak E, Dezube BJ, Yule M, Ayrton J, Lyons J and Mahadevan D: First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin Cancer Res. 21:87–97. 2015. View Article : Google Scholar
22	National Library of Medicine National Institutes of Health: Onalespib, Dabrafenib, and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that are metastatic or cannot Be removed by surgery. 2019
23	Spiegelberg D, Dascalu A, Mortensen AC, Abramenkovs A, Kuku G, Nestor M and Stenerlöw B: The novel HSP90 inhibitor AT 13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells. Oncotarget. 6:35652–35666. 2015. View Article : Google Scholar : PubMed/NCBI
24	Townsend CM Jr, Ishizuka J and Thompson JC: Studies of growth regulation in a neuroendocrine cell line. Acta Oncol. 32:125–130. 1993. View Article : Google Scholar : PubMed/NCBI
25	Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM and Park JG: Expression of neuro-endocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 48:4078–4082. 1988.PubMed/NCBI
26	Banks-Schlegel SP, Gazdar AF and Harris CC: Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res. 45:1187–1197. 1985.PubMed/NCBI
27	Friedrich J, Seidel C, Ebner R and Kunz-Schughart LA: Spheroid-based drug screen: Considerations and practical approach. Nat Protoc. 4:309–324. 2009. View Article : Google Scholar : PubMed/NCBI
28	Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al: Fiji: An open-source platform for biological-image analysis. Nat Methods. 9:676–682. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
30	Zitzmann K, Ruden J, Brand S, Göke B, Lichtl J, Spöttl G and Auernhammer CJ: Compensatory activation of Akt in response to mTOR and Raf inhibitors-a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 295:100–109. 2010. View Article : Google Scholar : PubMed/NCBI
31	Briest F and Grabowski P: PI3K-AKT-mTOR-signaling and beyond: The complex network in gastroenteropancreatic neuro-endocrine neoplasms. Theranostics. 4:336–365. 2014. View Article : Google Scholar :
32	Spiegelberg D, Mortensen AC, Selvaraju RK, Eriksson O, Stenerlöw B and Nestor M: Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model. Eur J Nucl Med Mol Imaging. 43:974–982. 2016. View Article : Google Scholar :
33	Beck R, Verrax J, Gonze T, Zappone M, Pedrosa RC, Taper H, Feron O and Calderon PB: Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol. 77:375–383. 2009. View Article : Google Scholar
34	Beck R, Dejeans N, Glorieux C, Creton M, Delaive E, Dieu M, Raes M, Levêque P, Gallez B, Depuydt M, et al: Hsp90 is cleaved by reactive oxygen species at a highly conserved N-terminal amino acid motif. PLoS One. 7:e407952012. View Article : Google Scholar : PubMed/NCBI
35	Ding D, Zhang Y, Wang J, Zhang X, Gao Y, Yin L, Li Q, Li J and Chen H: Induction and inhibition of the pan-nuclear gamma-H2AX response in resting human peripheral blood lymphocytes after X-ray irradiation. Cell Death Discov. 2:160112016. View Article : Google Scholar : PubMed/NCBI